Oncotelic Therapeutics Integrates 28 Million Scientific Abstracts into AI Platform, Signaling Shift in Drug Discovery

Artificial intelligence is rapidly becoming the defining infrastructure layer of modern drug development, and companies that control the most intelligent platforms may ultimately control the industry's future. Among the clinical-stage players quietly positioning themselves at the center of this shift is Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company that has spent years building a proprietary AI platform and is now turning that platform into something more ambitious than a drug-discovery tool.

The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts into its PDAOAI platform. This integration transforms the platform from a research accelerator for internal programs into a comprehensive knowledge engine capable of uncovering novel drug targets, predicting drug interactions, and identifying repurposing opportunities at unprecedented scale.

The broader market context makes Oncotelic's strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching more than $10 billion, according to industry reports. Oncotelic's central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs.

By ingesting such a vast corpus of scientific literature, Oncotelic aims to create a competitive moat that larger pharmaceutical companies may find difficult to replicate. The company's approach demonstrates how small biotech firms can out-innovate big pharma by focusing on niche, high-value technologies. While major drugmakers often rely on partnerships or acquisitions to access AI capabilities, Oncotelic has built its platform in-house, giving it greater control over the data and algorithms that drive discovery.

Investors and industry observers are taking note. The integration of 28 million abstracts is not merely a technical feat; it represents a strategic shift in how drug discovery can be conducted. Oncotelic's platform can now analyze vast amounts of data to generate hypotheses that would take years for human researchers to uncover. This capability is particularly valuable in oncology, where the complexity of disease biology demands sophisticated analytical tools.

For more information on Oncotelic's latest developments, visit the company's newsroom at ibn.fm/OTLC. The latest news and updates relating to OTLC are available there.

Oncotelic's progress underscores a broader trend: the convergence of AI and biotechnology is creating new opportunities for companies that can effectively harness computational power. As the AI in drug-discovery market expands, firms like Oncotelic that have invested early in proprietary platforms may be well-positioned to capture significant value.